One third of international clinical trials suspended in Russia

740

permits to conduct clinical trials in Russia were issued by the Ministry of Health last year. This is 18.5% less than in 2021. 93% of all local trials by foreign participants were generics (for domestic companies, this share was 78%). Basically, it was about drugs from Belarus (30.9% of the total) and India (29.6%). Russian companies received 162 permits to conduct local research in 2022 (+21.8%). Moreover, according to ACTO, the increase in the activity of domestic developers in the first half of last year was associated with the impact of the coronavirus pandemic, and not with the geopolitical crisis.